SHIELD THERAPEUTICS PLC — AGM Information 2017

Jun 13, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9743H

Shield Therapeutics PLC

13 June 2017

Shield Therapeutics plc

("Shield" or the "Group")

Result of Annual General Meeting

London, UK, 13 June 2017: Shield Therapeutics plc (LSE:STX), a speciality pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, announces that at its Annual General Meeting held today, all resolutions were duly passed.

-Ends-

For further information please contact:

Shield Therapeutics plc	+44 (0) 20 7467 6920
Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer
Nominated Adviser and Joint Broker	+44 (0)20 3100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker	+ 44 (0)20 7418 8900
Peel Hunt LLP
James Steel/Dr. Christopher Golden
Financial PR Advisor	+44 (0)203 709 5700
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal	shieldtherapeutics@consilium-comms.com

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGOKNDNNBKDCAD